OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Grant of Options
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that the Group's Remuneration Committee and the Board has, on 5 March 2021, approved the grant of 200,000 Options over ordinary shares of 4 pence each in the Company to Simon Douglas, Non-Executive Chairman, under the Company's Third Unapproved Option Scheme.
The Options were granted with an exercise price of 89 pence each, being the closing middle market price on 4 March 2021. The Options will vest over three years, one third vesting on each anniversary of the grant date. Following the grant, these Options represent Simon Douglas' only interest in the Company.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
| Omega Diagnostics Group PLC | |
| Colin King, Chief Executive | Via Walbrook PR |
| Kieron Harbinson, Group Finance Director | |
| | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/ Teddy Whiley (Corporate Finance) | |
| Alice Lane (ECM) | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Cawthorne | Mob: 07584 391 303 |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Simon Douglas | ||||||
| 2 | Reason for notification |
| ||||||
| a. | Position/Status | Non-Executive Chairman | ||||||
| b. | Initial notification/ Amendment | Initial Notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Omega Diagnostics Group Plc | ||||||
| b. | LEI | 2138007U9P4BTZTYIR92 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument | 200,000 Options over Ordinary Shares of 4 pence each were granted with an exercise price of 89 pence each. The Options will vest over three years, one third vesting on each anniversary of the grant date.
ISIN: GB00B1VCP282 | ||||||
| b. | Nature of the transaction | Granting of Share Options | ||||||
| c. | Price(s) and volume(s) | | | | | | ||
| | Price(s) | Volume(s) | | |||||
| 89p | 200,000 | | ||||||
| | ||||||||
| d. | Aggregated information
| As above.
| ||||||
| e. | Date of the transaction | 5 March 2021 | ||||||
| f. | Place of the transaction | London Stock Exchange | ||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
